The notices it replaced
- Reissues: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-15-270.
Who won it before
387 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $119,622,286 in first-year total cost, median $224,991.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-M (11)]34
- Special Emphasis Panel[ZRG1 SBIB-T (10)]27
- Special Emphasis Panel[ZRG1 OTC-T (10)]26
- Special Emphasis Panel[ZRG1 IMST-L (11)]17
- Special Emphasis Panel[ZRG1 IMST-M (13)]17
Most frequent institutions
- BARRON ASSOCIATES, INC.4
- CORTICOMETRICS, LLC4
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC4
- MICROBIOTIX, INC4
- COG ANALYTICS, LLC3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Peripheral FAAH as a target for novel analgesics2R42DA033683-02A1 | PIOMELLI, DANIELE | ANTEANA THERAPEUTICS, INC., CA | $1,100,244 | ZRG1 |
| 2016 | The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients1UT2HL131226-01 | RODRIGUEZ-BORLADO, LUIS | CAPRICOR, INC., CA | $1,683,381 | ZRG1 |
| 2016 | New generation of catheters for treatment of atrial fibrillation2R42HL120511-02 | SARVAZYAN, NARINE | NOCTURNAL PRODUCT DEVELOPMENT, LLC, NC | $1,173,082 | ZRG1 |
| 2016 | Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms2R42NS074576-03 | KALLMES, DAVID FKEALEY, COLIN PATRICK | NEUROSIGMA, INC., CA | $1,072,694 | ZRG1 |
| 2016 | A Phase 2a clinical trial of ALK-001 in geographic atrophy2R44EY021988-02A1 | SAAD, LEONIDEWASHINGTON, ILYAS | ALKEUS PHARMACEUTICALS, INC., MA | $1,054,287 | ZRG1 |
| 2016 | Clonotyping Technology for Prediction of Antibiotic Resistance2R42AI116114-02 | KAWASAKI, GLENNOSTER, JEFFREYSOKURENKO, EVGENI VENIAMINOVIC | IDGENOMICS, INC., WA | $999,967 | ZRG1 |
| 2016 | SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT2R42HL123126-02 | SACHAIS, BRUCE S | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $980,000 | ZRG1 |
| 2016 | Mutation Enriched Targeted Re-Sequencing2R42CA180389-02A1 | MAKRIGIORGOS, G. MIKEWU, GRANT | TRANSGENOMIC, INC., NE | $773,511 | ZRG1 |
| 2016 | The CellRaft AIR System: Workflow Automation for Stem Cell Isolation and Recovery2R42GM106421-02 | ALLBRITTON, NANCY L. | CELL MICROSYSTEMS, INC., NC | $748,655 | ZRG1 |
| 2016 | Memory Care Partner2R42AG044147-02A1 | ANDERSEN, TROYFOSTER, NORMAN LOUIS | PROACTIVE MEMORY SERVICES, INC., UT | $734,115 | ZRG1 |
| 2016 | Development of small near-infrared laser system capable of improving immune responses to vaccines (laser-based adjuvant)2R42AI114012-02 | BEAN, DAVID | VERALASE, LLC, MA | $696,264 | ZRG1 |
| 2016 | Single Cell Analysis via Nanoscale Tip-Enhanced Laser Ablation Mass Spectrometry2R42GM106454-02 | MURRAY, KERMIT KING | ANASYS INSTRUMENTS CORPORATION, CA | $597,820 | ZRG1 |
| 2016 | High-potency nitro antimicrobials for topical treatment of trichomoniasis1R41AI118089-01A1 | ECKMANN, LARSPEYTON, DAVID H | DESIGNMEDIX, INC., OR | $353,902 | ZRG1 |
| 2016 | A microfluidic quality-control assay for stem-cell derived therapies1R41TR001203-01A1 | NEUMANN, THOMAS | NORTIS, INC., WA | $325,000 | ZRG1 |
| 2016 | T3SS needle protein inhibitors for the treatment of P. aeruginosa infection1R41AI122433-01 | MECSAS, JOAN C | MICROBIOTIX, INC, MA | $302,983 | ZRG1 |
| 2016 | Combinatorial Inactivation of ERBB Receptors in Breast Cancer using Therapeutic Stapled Peptides1R41CA203353-01 | SCHROEDER, JOYCE A | ARIZONA CANCER THERAPEUTICS, LLC, AZ | $300,000 | ZRG1 |
| 2016 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer1R41CA200161-01A1 | SONENSHEIN, GAIL E. | ADECTO PHARMACEUTICALS, INC., MA | $300,000 | ZRG1 |
| 2016 | Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma1R41CA195908-01A1 | WAJAPEYEE, NARENDRA | L2 DIAGNOSTICS, LLC, CT | $298,959 | ZRG1 |
| 2016 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development1R41CA203090-01 | UNGER, EVAN CHARLESWILLMANN, JUERGEN KARL | NUVOX PHARMA, LLC, AZ | $297,786 | ZRG1 |
| 2016 | Novel antibacterial agents derived from natural products1R41AI118104-01A1 | PRIESTLEY, NIGEL D | PROMILIAD BIOPHARMA, INC., MT | $295,729 | ZRG1 |
| 2016 | Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria1R41AI115915-01A1 | JUNG, DAVID | AGILE SCIENCES, INC., NC | $294,309 | ZRG1 |
| 2016 | Development of Optimized AAV Serotype Vectors for Human Gene Therapy1R41AI122735-01 | SRIVASTAVA, ARUN | MEDOSOME BIOTEC, LLC, FL | $294,094 | ZRG1 |
| 2016 | A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development1R41CA195777-01A1 | LIU, JASMINE JINGYUAN | QRKANSWER, IN | $279,838 | ZRG1 |
| 2016 | Novel SCD1 inhibitors for treatment of cancer1R41CA195946-01A1 | COPLAND, JOHN A.HAZLEHURST, LORI | MODULATION THERAPEUTICS, INC., WV | $279,000 | ZRG1 |
| 2016 | An epitope-focused nanoparticle vaccine for MRSA and biodefense1R41AI122594-01 | OSCHERWITZ, JONWHITACRE, DAVID C | VLP BIOTECH, INC., CA | $273,748 | ZRG1 |
| 2016 | Digital Gene Expression Analysis by 3’ End Sequencing1R41HG008921-01 | TIAN, BINTOLOUE, MASOUD | BIOO SCIENTIFIC CORPORATION, TX | $270,000 | ZRG1 |
| 2016 | Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions1R41GM116530-01A1 | NAGY, JON OWENWONG, JOYCE Y | NANOVALENT PHARMACEUTICALS, INC., MT | $238,728 | ZRG1 |
| 2016 | Biological super-resolution imaging using high-index microspheres for cancer research application1R41GM117844-01 | CARABE-FERNANDEZ, ALEJANDRODARAFSHEH, ARASHLEE, DAEYEON | SPHEREVIS, LLC, PA | $233,419 | ZRG1 |
| 2016 | Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants1R41AI118522-01A1 | DANLEY, DAVID LAWRENCE | PARABON NANOLABS, INC., VA | $230,000 | VACC |
| 2016 | Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease1R41AI122403-01 | AMAN, M JAVADLAI, JONATHAN R. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $229,991 | ZRG1 |
| 2016 | PEGYLATED PEPTIDES LIGANDS TARGETING RADIATION-INDUCIBLE RECEPTORS ON CANCER1R41CA196002-01A1 | DEVANATHAN, SRIRAM | MEDICAL GUIDANCE SYSTEMS, LLC, MO | $225,000 | ZRG1 |
| 2016 | Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species1R42ES026532-01 | ZYUZIN, ALEXEI | ILLIONIX, LLC, WA | $225,000 | ZRG1 |
| 2016 | Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy1R41GM117974-01 | POWELL, RICHARD DENIS | NANOPROBES, INC., NY | $225,000 | ZRG1 |
| 2016 | Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis1R41CA196011-01A1 | ORTON, DARREN | STEMSYNERGY THERAPEUTICS, INC., FL | $224,991 | ZRG1 |
| 2016 | Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus1R41AI122566-01 | PROBST, PETERSTEVENS, ANNE MARGUERITE | KINETA, INC., WA | $224,977 | ZRG1 |
| 2016 | Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing1R41TR001270-01A1 | CURLEY, JABE LMOORE, MICHAEL J | AXOSIM, INC., LA | $224,859 | ZRG1 |
| 2016 | Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects1R41AI122574-01 | VANDENBARK, ARTHUR A. | VIROGENOMICS BIODEVELOPMENT, INC., OR | $224,796 | ZRG1 |
| 2016 | Shape RNA Structure Analysis for Drug Discovery and Translational Research1R43GM116274-01 | WARNER, KATHERINE DEIGAN | RIBOMETRIX, LLC, NC | $224,700 | ZRG1 |
| 2016 | Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes1R42DK108305-01 | KLEIN, SAMUELTHAI, DUNG L | REMD BIOTHERAPEUTICS, INC., CA | $224,664 | ZRG1 |
| 2016 | SHAPE RNA Bioinformatics for Therapeutics and Translational Research1R41GM117712-01 | WEEKS, KEVIN M | RIBOMETRIX, LLC, NC | $224,636 | ZRG1 |
| 2016 | Device for Treatment of Congenital Diaphragmatic Hernia1R41HL131250-01 | GOLDMAN, KENNETH GLEN | H-CUBED, INC., OH | $224,634 | ZRG1 |
| 2016 | improving Cas9 mediated homologous recombination in pluripotent stem cells1R41GM115028-01A1 | ZHANG, JIFENG | APPLIED STEMCELL, INC., CA | $224,518 | ZRG1 |
| 2016 | Engineering stem cells to make mucopolysaccharidosis IIIB1R41NS092221-01A1 | EKINS, SEAN | PHOENIX NEST, INC., NY | $224,469 | ZRG1 |
| 2016 | Novel therapies for inherited muscle diseases1R41AR068158-01A1 | KANG, PETER B. | MEDOSOME BIOTEC, LLC, FL | $224,463 | ZRG1 |
| 2016 | New piperazines effecting Abeta oligomer displacement from neuronal receptors1R41AG052252-01 | IZZO, NICHOLAS JOHN | COGNITION THERAPEUTICS, INC., PA | $224,002 | ZRG1 |
| 2016 | Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain1R41NS095436-01 | KOPIN, ALAN S | ON TARGET THERAPEUTICS, LLC, MA | $223,900 | ZRG1 |
| 2016 | Dual-view endoscopic probe1R41CA203212-01 | BANERJEE, BHASKARCOOMBS, DAVID | OMNISCIENT IMAGING, INC., AZ | $223,761 | ZRG1 |
| 2016 | Sample-free onsite detection of cocaine using microneedles via laser-treated skin1R41DA041003-01 | WU, MEI XXIE, XINMIN SIMON | AFASCI, INC., CA | $223,633 | ZRG1 |
| 2016 | Delivery of pathogen-trapping antibodies for vaginal protection1R41AI122472-01 | MOENCH, THOMAS RAY | MUCOMMUNE, LLC, NC | $222,725 | ZRG1 |
| 2016 | An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care1R41HD087021-01 | KASSAM-ADAMS, NANCYMCLAUGHLIN, JEFFERY | RADIANT CREATIVE GROUP, LLC, TX | $220,945 | ZRG1 |
| 2016 | A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes1R41AR068202-01A1 | LOTZ, JEFFREY C. | BIONIKS, INC., CA | $215,600 | MRS |
| 2016 | Optimization of a computationally designed antiviral for influenza1R41AI122431-01 | FULLER, DEBORAH H.KODAY, MERIKA TREANTS | VIRVIO, INC., WA | $209,358 | ZRG1 |
| 2016 | Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents1R41CA203571-01 | JAY, MICHAEL | CAPTURE PHARMACEUTICALS, INC, NC | $205,593 | ZRG1 |
| 2016 | Enabling Nanomembrane-Based Biomolecule and Nanoparticle Separations1R41GM116190-01A1 | MCGRATH, JAMES L | SIMPORE, INC., NY | $198,938 | ZRG1 |
| 2016 | Computerizing NIAAA's Best Practices for Youth Screening and Brief Intervention1R41AA024354-01A1 | MITCHELL, SHANNON GWIN | COG ANALYTICS, LLC, MD | $198,521 | ZRG1 |
| 2016 | development of immunodeficient rabbit models1R41AI122510-01 | XU, JIE | CELETRIX, LLC, VA | $186,180 | ZRG1 |
| 2016 | Novel immunotherapy strategy for treatment of pancreatic cancer1R41CA195947-01A1 | MUKHERJEE, PINKU | ONCOTAB, INC, NC | $182,461 | ZRG1 |
| 2016 | Treating collagen-induced arthritis (CIA) with immunoregulatory nanoparticles1R41AR068161-01A1 | MOSSER, DAVID M | LEUKOSIGHT, INC., MD | $179,502 | ZRG1 |
| 2016 | ARCHER - An Extremely Fast Medical Radiation Dose Computing Software1R42EB019265-01A1 | XU, XIE GEORGE | VIRTUAL PHANTOMS, INC., NY | $165,220 | ZRG1 |
| 2016 | Advanced Cannula Development for Coronary Sinus Access1R41HL129754-01A1 | SPOTNITZ, HENRY MICHAEL | STRATEGIC PACING SYSTEMS, LLC, NJ | $158,680 | ZRG1 |
| 2016 | Development of Alkontrol herbal for Treating Alcohol Abuse1R42AA022577-01A1 · under PA-13-235 | LI, HAIXIALUKAS, SCOTT E | NATURAL PHARMACIA INTERNATIONAL, INC., MA | $154,747 | ZRG1 |
| 2016 | Mobile Intervention Kit to Increase HIV/HCV Testing and Overdose Prevention Training1R41DA041246-01 | ARONSON, IAN DAVID | DIGITAL HEALTH EMPOWERMENT, INC., NY | $152,762 | ZRG1 |
| 2016 | Clinical real-time resting state fMRI1R41NS090691-01A1 | POSSE, STEFAN | NEURINSIGHT, LLC, NM | $150,000 | ZRG1 |
| 2016 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment1R41DE025789-01 | EBETINO, FRANK H.SEDGHIZADEH, PARISH PAYMON | BIOVINC, LLC, CA | $149,963 | ZRG1 |
| 2016 | Optimization of small molecule triazine antituberculars for in vivo efficacy1R41AI122434-01 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $149,388 | ZRG1 |
| 2016 | Single-Molecule Analyte Detection by Molecular Motor-driven Nanodevices1R41GM115039-01 | FRASCH, WAYNE D | ATTOMETRICS, LLC, AZ | $149,265 | ZRG1 |
| 2015 | Novel commensal polysaccharide treats multiple sclerosis through Treg modulation2R42AI110170-02 | KASPER, LLOYD H | SYMBIOTIX BIOTHERAPIES, INC., MA | $2,264,726 | ZRG1 |
| 2015 | Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma2R42CA153845-02 | SAMPSON, JOHN H. | ANNIAS IMMUNOTHERAPEUTICS, INC., CA | $1,227,385 | ZRG1 |
| 2015 | Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy2R42CA176951-02A1 | RITTENHOUSE-OLSON, KATE W | FOR-ROBIN, NY | $973,366 | ZRG1 |
| 2015 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder2R42MH091997-03A1 | BOWDEN, CHARLES LEEPRIESMEYER, RICHARD | BIOMEDICAL DEVELOPMENT CORPORATION, KY | $869,569 | ZRG1 |
| 2015 | Live-Cell Fluorescence Lifetime FRET Assays for HTS2R42DA037622-03 | GILLISPIE, GREGORY DAVID | FLUORESCENCE INNOVATIONS, INC., MN | $860,487 | ZRG1 |
| 2015 | Stroke Treatment by Chemically-induced Hypothermia2R42NS073378-03A1 | DIX, THOMAS A.YU, SHAN P. | JT PHARMACEUTICALS, INC., SC | $793,793 | ZRG1 |
| 2015 | Computer-aided detection of focal cortical dysplasias2R44NS083101-02A1 | FISCHL, BRUCESCHMANSKY, NICHOLAS JOHN | CORTICOMETRICS, LLC, MA | $750,677 | ZRG1 |
| 2015 | Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT2R42HL114206-02 | ABRAMSON, JONATHAN J | ELEX BIOTECH, LLC, OR | $750,385 | ZRG1 |
| 2015 | Phase IIB: Portable Device for Telecare Monitoring of Elderly People2R42AG032748-04 | GWIN, JOSEPH TMOHLER, MARTHA JANENAJAFI, BIJAN | BIOSENSICS, LLC, MA | $749,999 | ZRG1 |
| 2015 | Calibrated Methods for Quantitative PET/CT Imaging Phase II2R42CA167907-02 | ENQUOBAHRIE, ANDINET ASMAMAWKINAHAN, PAUL E. | KITWARE, INC., NY | $740,435 | ZRG1 |
| 2015 | Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing2R42CA174121-02 | CIVIN, CURT ISTURM, JAMES C | GPB SCIENTIFIC, INC., VA | $739,526 | ZRG1 |
| 2015 | Evidenced-based Firefighter Worksite Health and Safety Intervention2R42TR000357-02 · under PA-13-235 | ELLIOT, DIANE LOUISEGOLDBERG, LINN | ODYSSEY SCIENCE INNOVATIONS, LLC, OR | $714,294 | ZRG1 |
| 2015 | Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)2R42AA022035-03 | BOUDREAUX, EDWIN D | POLARIS HEALTH DIRECTIONS, INC., PA | $693,416 | ZRG1 |
| 2015 | Lentiviral Vector for the treatment of Fanconi Anemia2R42HL099150-02A1 | GOEBEL, WILLIAM SCOTT | RIMEDION, INC., CA | $690,143 | ZRG1 |
| 2015 | Polaris Oncology Survivor Transition (POST) System2R42CA174048-03 | O'HEA, ERIN LEE | POLARIS HEALTH DIRECTIONS, INC., PA | $684,311 | ZRG1 |
| 2015 | Multimodality Image-Based Assessment System for Traumatic Brain Injury2R44NS081792-03A1 | AYLWARD, STEPHEN RNIETHAMMER, MARCVAN HORN, JOHN DARRELL | KITWARE, INC., NY | $635,667 | ZRG1 |
| 2015 | Using game mechanics to improve outcomes among stem cell transplant survivors2R42CA168107-02 | ASKINS, MARTHA ANNMCLAUGHLIN, JEFFERYPETERSON, SUSAN KZHANG, DONGSONG | RADIANT CREATIVE GROUP, LLC, TX | $616,412 | ZRG1 |
| 2015 | Development of a novel method for inhibiting diabetic retinopathy2R42EY021943-02A1 | CLEMMONS, DAVID R | CMP TARNHELM PARTNERS, LLC, NC | $583,208 | ZRG1 |
| 2015 | Improving Outcomes for Mechanically Ventilated Patients with the Digital EZ Board2R42NR014087-02 | HAPP, MARY E | VIDATAK, LLC, MI | $579,646 | ZRG1 |
| 2015 | A crosslinked cartilage-derived matrix for cartilage tissue engineering2R44AR061916-02 | ESTES, BRADLEY T | CYTEX THERAPEUTICS INC., NC | $570,289 | ZRG1 |
| 2015 | Neuroimaging tools for presurgical brain mapping2R42CA173976-02 | DEYOE, EDGAR APILLAI, JAY J | PRISM CLINICAL IMAGING INC., WI | $552,991 | ZRG1 |
| 2015 | IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS2R42ES022530-02 | CHRISTENSON, MARK | AIRLIFT ENVIRONMENTAL, LLC, NE | $540,036 | ZRG1 |
| 2015 | A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus1R41AI115906-01 | JOHNSTON, ROBERT E. | ALTRAVAX, INC., CA | $532,838 | ZRG1 |
| 2015 | Design, Development, and Evaluation of an Interactive Tactile Graphics Printer for the Blind and VisuallyImpaired2R42TR000376-02A1 | ROSEN, MICHAEL J. | EASY, LLC, VT | $508,209 | ZRG1 |
| 2015 | A Force-controlled Probe Based Platform for Single-Cell Biomolecular Delivery2R44GM101833-02 · under PA-13-235 | YANG, RUIGUO | INFINITESIMAL, LLC, IL | $499,999 | ZRG1 |
| 2015 | Enhanced multiphoton microscopy through spatial light modulation2R42MH102201-02 | HOY, CHRISTOPHER LUK | BOULDER NONLINEAR SYSTEMS, INC., CO | $496,726 | ZRG1 |
| 2015 | AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P2R42GM100657-02 · under PA-13-235 | TAYLOR, LYNNE S | ANASYS INSTRUMENTS CORPORATION, CA | $495,193 | ZRG1 |
| 2015 | Protein Sequencing Tools for Biological Therapeutics2R42GM103362-03 | FENYO, DAVID | PROTEIN METRICS, LLC, CA | $494,418 | ZRG1 |
| 2015 | IMMEDIATE FIT USING INNOVATIVE TECHNOLOGY TRANSTIBIAL PROSTHESIS2R42AG050430-04 | DILLINGHAM, TIMOTHY R | IFIT PROSTHETICS, LLC, WI | $474,565 | MRS |
| 2015 | APPSPIRE: expanding the reach of an innovative tobacco control program for youth2R42DA035012-02 | MCLAUGHLIN, JEFFERYPROKHOROV, ALEXANDER V | RADIANT CREATIVE GROUP, LLC, TX | $446,282 | ZRG1 |
| 2015 | Development of novel compounds for the treatment of atrial fibrillation1R41HL129570-01 | WEHRENS, XANDER H.T. | ELEX BIOTECH, LLC, OR | $427,638 | ZRG1 |
| 2015 | ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI1R41NS093756-01 | LECHLEITER, JAMES D | ASTROCYTE PHARMACEUTICALS, INC., MA | $420,239 | ZRG1 |
| 2015 | RAP as a novel therapeutic to promote remyelination after MS demyelinating event1R43NS092182-01A1 | GAULTIER, ALBAN PSTILES, TRAVIS LEE | NOVORON BIOSCIENCE, INC., CA | $353,106 | ZRG1 |
| 2015 | Selective inhibitors of Heme Transporters as Antiparasitic Agents1R41AI113998-01A1 | HAMZA, IQBAL | RAKTA THERAPEUTICS, INC., MD | $350,126 | ZRG1 |
| 2015 | Rational design of small interfering RNA for genome-wide target knockdown1R41HG008567-01A1 | LIU, WEIJUNWANG, XIAOWEI | NAWGEN, LLC, IL | $347,147 | ZRG1 |
| 2015 | HLS13-13 Albumin nanoparticle based technology to treat ARDS1R41HL126456-01 | MALIK, ASRAR B. | CELL BIOLOGICS, INC., IL | $344,039 | ZRG1 |
| 2015 | Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections1R41AI115897-01 | DAVEY, ROBERT A | OMM SCIENTIFIC, INC., TX | $328,211 | ZRG1 |
| 2015 | A novel drug detection assay using fluorescent biosensor technology1R41GM110813-01A1 | MELCHIOR, DONALD LEE | GLSYNTHESIS, INC., MA | $320,466 | ZRG1 |
| 2015 | Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis1R41HL127919-01 | BUCK, MARTINACHOJKIER, MARIO | XFIBRA, INC., CA | $316,111 | ZRG1 |
| 2015 | DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES1R41AI113952-01A1 | HARTY, RONALD N | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2015 | Developing therapeutic inhibitors of CIB1 for breast cancer1R41CA200189-01 | FRYE, STEPHEN VERNONPARISE, LESLIE | REVERIS THERAPEUTICS, LLC, NC | $300,000 | ZRG1 |
| 2015 | A Low-Cost Portable Multiplex Serum Molecular Test for HBV and HCV Detection1R41AI120445-01 | SHIH, WAN Y. | LENIMA FIELD DIAGNOSTICS, LLC, PA | $300,000 | ZRG1 |
| 2015 | Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease1R41CA195826-01 | FRETT, BRENDAN ANDREWLI, HONG YU | SYNACTIX PHARMACEUTICALS, INC., AZ | $299,975 | ZRG1 |
| 2015 | GPCR antagonists as anti-Ebola virus entry inhibitors1R41AI120437-01 | RONG, LIJUN | MICROBIOTIX, INC, MA | $299,392 | ZRG1 |
| 2015 | RSK3 Anchoring Disruptor Therapy for Heart Failure1R41HL129524-01 | KAPILOFF, MICHAEL SETH | ANCHORED RSK3 INHIBITORS, LLC, CA | $299,024 | ZRG1 |
| 2015 | Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells1R41CA192689-01 | SZOKA, FRANCIS C. | ZONEONE PHARMA, INC., CA | $298,920 | ZRG1 |
| 2015 | Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction1R41AG052249-01 | IZZO, NICHOLAS JOHN | COGNITION THERAPEUTICS, INC., PA | $298,527 | ZRG1 |
| 2015 | Treatment of Acute Radiation Syndrome using PIF, a Natural Immune Modulator1R41AI120546-01 | PAIDAS, MICHAEL JOHN | BIOINCEPT, LLC, OH | $298,309 | ZRG1 |
| 2015 | Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application1R42HL127933-01 | NICHOLS, SCOTTWISNIEWSKI, NATALIE ANN | PROFUSA, INC., CA | $296,345 | ZRG1 |
| 2015 | Distance Filtering System for Retinal Implants1R42EY025136-01A1 | DAGNELIE, GISLIN | ADVANCED MEDICAL ELECTRONICS CORPORATION, MN | $296,344 | ZRG1 |
| 2015 | Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core1R41AI118122-01 | RONG, LIJUN | MICROBIOTIX, INC, MA | $288,568 | ZRG1 |
| 2015 | Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy1R41AI118037-01 | MAIRA-LITRAN, TOMAS | MICROBIOTIX, INC, MA | $288,494 | ZRG1 |
| 2015 | Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.1R41CA199753-01 | LI, HONG YUSHAH, NEIL P | PROMUTECH PHARMACEUTICALS, INC., AZ | $285,792 | ZRG1 |
| 2015 | Infant Screening of Early Communication Risk: The CISS, Phase II2R42DC013506-02 | CRESS, CYNTHIA J | PAUL H. BROOKES PUBLISHING COMPANY, INC., MD | $280,968 | ZRG1 |
| 2015 | Mechanistic Studies of a Novel Small Molecule HIV Inhibitor1R41GM115250-01 | NAKAMURA, ROBERT | ADVANCED GENETIC SYSTEMS, INC., CA | $277,424 | ADDT |
| 2015 | Development of novel lung cancer therapeutics targeting the DNA damage response1R41CA195926-01 | PAWELCZAK, KATHERINETURCHI, JOHN J. | NERX BIOSCIENCES, INC., IN | $249,431 | ZRG1 |
| 2015 | Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.1R41CA196026-01 | MCLAUGHLIN, MARK LMORSE, DAVID LPILON-THOMAS, SHARI | MODULATION THERAPEUTICS, INC., WV | $244,801 | ZRG1 |
| 2015 | Technology-Guided Opioid Cessation for Post-Operative Pain1R41DA039640-01 | CARROLL, IAN RICHARDDAVIS, MICHAEL SEAN | MEDICASAFE, INC., NY | $243,321 | ZRG1 |
| 2015 | Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes1R41HL127901-01A1 | BETT, GLENNA C L | CYTOCYBERNETICS, INC., NY | $241,933 | ZRG1 |
| 2015 | Urine Diagnostics for Aspergillosis1R41AI115866-01 | MARR, KIEREN A. | PEARL DIAGNOSTICS, INC., MD | $238,175 | ZRG1 |
| 2015 | Intranasal Sulfamidase Delivery to the Brain1R43NS089383-01A1 | GLASS, CHARLES ALEXANDER | TEGA THERAPEUTICS, INC., CA | $237,138 | ZRG1 |
| 2015 | Neurotrophic Agents for Treating Parkinson's Disaese1R41NS089140-01A1 | DEFREES, SHAWN | SENEB BIOSCIENCES, INC., CT | $233,804 | ZRG1 |
| 2015 | A Visual Assessment System for Retinal Function/Drug Discovery1R41EY025913-01 | CHEN, DONG FENGLUO, GANGXIE, XINMIN SIMON | AFASCI, INC., CA | $233,235 | ZRG1 |
| 2015 | S-Nitrosothiol-Based Rinse/Aerosol Solutions For Treatment/Prevention of Rhinosinusitis1R41AI120443-01 | HERSHENSON, MARC B.MEYERHOFF, MARK EQIN, YU | NOTA LABORATORIES, LLC, MI | $232,832 | ZRG1 |
| 2015 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction1R42DA040422-01 | FUJII, GARY | MOLECULAR EXPRESS, INC., CA | $225,033 | ZRG1 |
| 2015 | INTELLIGENT MOUTHGUARD FOR MEASURING HEAD IMPACTS IN YOUTH ATHLETES1R41HD079158-01A1 | BARTSCH, ADAM JESSE | SPORTSGUARD LABORATORIES, INC., OH | $225,000 | ZRG1 |
| 2015 | Small Molecules To Inhibit PCSK9-LDLR1R41HL126346-01 | BURGESS, KEVIN | SMALL MOLECULE PPI MIMICS, LLC, TX | $225,000 | ZRG1 |
| 2015 | Axonal Transport HTS Platform for Neurodegeneration Drug Discovery1R41NS090693-01 | BEEBE, DAVID JLOWERY, ROBERT G | BELLBROOK LABS, LLC, WI | $225,000 | ZRG1 |
| 2015 | Novel adjuvant therapy for triple negative breast cancer1R41CA183399-01A1 | GONZALEZ-PEREZ, RUBEN RENE | JYANT, INC., GA | $225,000 | ZRG1 |
| 2015 | A Novel Approach to Purifying iPSC Derived Cell Cultures1R41GM114935-01 | TENENBAUM, SCOTT A | HOCUSLOCUS, INC., NY | $225,000 | ZRG1 |
| 2015 | Contraceptive testing for semen availability in male monkeys1R41HD084077-01 | ORAND, MICHAEL GENE | EPPIN PHARMA, INC., NC | $225,000 | ZRG1 |
| 2015 | Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses1R41CA192600-01A1 | CAI, WENLIWU, YIN | IQ MEDICAL IMAGING, LLC, MA | $225,000 | ZRG1 |
| 2015 | A Tool for Research on Emotion in Naturally Occurring Speech1R41LM012177-01 | CRANGLE, COLLEEN ELIZABETHLONGINO, HELEN E | CONVERSPEECH, LLC, CA | $225,000 | ZRG1 |
| 2015 | mTOR Substrate Phosphorylation: A New Bioassay for Therapeutics1R41NS093970-01 | CRINO, PETER B | COGNIZANCE BIOMARKERS, LLC, PA | $225,000 | ZRG1 |
| 2015 | sxRNA-based Antiviral Approach targeting Epstein-Barr virus1R41AI115834-01A1 | BHADURI-MCINTOSH, SUMITA | HOCUSLOCUS, INC., NY | $225,000 | ZRG1 |
| 2015 | Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis1R41AR068816-01 | DAMSKER, JESSE | REVERAGEN BIOPHARMA, INC., MD | $225,000 | ZRG1 |
| 2015 | Novel piperazine tethered thiazole compounds as antimalarials1R41AI120351-01 | MICHAELS, HEATHER ANN | SMART BIOMOLECULES, INC., FL | $225,000 | ZRG1 |
| 2015 | Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis1R42AR067617-01A1 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $225,000 | ZRG1 |
| 2015 | Mapping electrogram morphology recurrence for atrial fibrillation ablation1R41HL127907-01A1 | NG, JASON | GOLD T-TECH, INC., FL | $225,000 | ZRG1 |
| 2015 | A Structural Brain MRI Dementia Forecast Tool1R41AG052246-01 | SABUNCU, MERT RORYSCHMANSKY, NICHOLAS JOHN | CORTICOMETRICS, LLC, MA | $225,000 | ZRG1 |
| 2015 | Biological treatment of bacterial keratitis1R41EY024475-01A1 | BRANDT, CURTIS RFILUTOWICZ, MARCIN SMOSER, MICHAEL JAMES | AMEBAGONE, INC., WI | $224,999 | ZRG1 |
| 2015 | New Class of Bright, Sharp, Tunable Red/Far-Red Fluorophores for Flow Cytometry1R41EB020470-01 | PITNER, JAMES BRUCE | NIRVANA SCIENCES, INC., NC | $224,999 | ZRG1 |
| 2015 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy1R41AR067019-01A1 | BURKIN, DEAN J. | STRYKAGEN CORPORATION, NV | $224,999 | ZRG1 |
| 2015 | PDE4B Inhibitors for Treating Brain Injury1R41NS090666-01A1 | GURNEY, MARK E | TETRA DISCOVERY PARTNERS, INC., MI | $224,999 | ZRG1 |
| 2015 | Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system1R41AI120353-01 | BOWEN, WILLIAM SEANLAWRENZ, MATTHEW BSHIRWAN, HAVAL | FASCURE THERAPEUTICS, LLC, KY | $224,999 | ZRG1 |
| 2015 | AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement1R41AG052223-01A1 | BEAUMONT, RYAN MICHAELCACCESE, VINCENT | RM BEAUMONT CORPORATION, ME | $224,999 | MRS |
| 2015 | Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation1R41DK108397-01 | KAUFMAN, JONATHAN H | LIPELLA PHARMACEUTICALS, INC., PA | $224,999 | ZRG1 |
| 2015 | Smartphone Technology for Parents and Teens: Improving Vaccination Uptake1R41HD082901-01A1 | WOODALL, W GILL | KLEIN BUENDEL, INC., CO | $224,998 | ZRG1 |
| 2015 | Speech Enhancement Based on Auditory Coding of Voiced Signals1R41DC013916-01A1 | CARNEY, LAUREL H. | OMNISPEECH, LLC, MD | $224,997 | ZRG1 |
| 2015 | Restimulating memory T cell responses in elderly by a novel, live influenza vaccine1R41AI120269-01 | BILSEL, PAMUKIWASAKI, AKIKO | FLUGEN, INC., WI | $224,997 | ZRG1 |
| 2015 | Enhancing Care of the Aged and Dying in Prisons1R41AG049570-01 | PENROD, JANICE L | KLEIN BUENDEL, INC., CO | $224,986 | ZRG1 |
| 2015 | Directed Antifungal Therapy for HIV-associated Cryptococcal Meningitis1R41AI120751-01 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $224,976 | ZRG1 |
| 2015 | Development of Therapeutics to Treat Candida albicans Biofilm Infections1R41AI112038-01A1 | NOBILE, CLARISSA JANE | BIOSYNESIS, INC., CA | $224,956 | ZRG1 |
| 2015 | New Assays for Expression Profiling of MicroRNAs1R41HG008247-01A1 | LIU, WEIJUNWANG, XIAOWEI | NAWGEN, LLC, IL | $224,951 | ZRG1 |
| 2015 | Delivery of peptides for inducing voiding associated with neurological retention1R41NS092178-01 | MARSON, LESLEY | DIGNIFY THERAPEUTICS, LLC, NC | $224,946 | ZRG1 |
| 2015 | Therapeutic Antibodies for Biofilm Infections1R41AI120425-01 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $224,946 | ZRG1 |
| 2015 | Knee-Biofeedback Rehabilitation Interface for Game-based Home Therapy (KneeBRIGHT)1R41AR067562-01A1 | KREPKOVICH, EILEEN T. | BARRON ASSOCIATES, INC., VA | $224,925 | ZRG1 |
| 2015 | Strength and BALance (SABAL) Virtual Trainer1R41AG046958-01A1 | ADAMS, RICHARD J. | BARRON ASSOCIATES, INC., VA | $224,918 | ZRG1 |
| 2015 | Development of a Novel Therapeutic Approach for Cryptococcal Meningitis1R41AI120304-01 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $224,917 | ZRG1 |
| 2015 | Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction1R41DA039632-01 | HUCKANS, MARILYNLOFTIS, JENNIFER M | VIROGENOMICS BIODEVELOPMENT, INC., OR | $224,886 | ZRG1 |
| 2015 | Novel Activin A Antagonists for Treatment of Osteoporosis1R41AR068804-01 | MARTINEZ HACKERT, ERIK MATTHIASMESSMER, BRADLEY T | ABREOS BIOSCIENCES, INC., CA | $224,811 | ZRG1 |
| 2015 | Developing a Diagnostic Blood Test for Sarcoidosis1R41HL129728-01 | MOLLER, DAVID ROBERT | SARCOIDOSIS DIAGNOSTIC TESTING, LLC, NJ | $224,780 | ZRG1 |
| 2015 | Lactoferrin Modulation of Granuloma Pathology1R41AI117990-01 | ACTOR, JEFFREY KKRUZEL, MARIAN L | PHARMAREVIEW CORPORATION, TX | $224,725 | ZRG1 |
| 2015 | Interactive technology for media literacy drug prevention in community groups1R41DA039595-01 | GREENE, KATHRYN LHECHT, MICHAEL | REAL PREVENTION, LLC, NJ | $224,630 | ZRG1 |
| 2015 | Portable Multimode Persufflation/Perfusion System for Extended Hypothermic Kidney Preservation1R41DK108620-01 | PAPAS, KLEARCHOS KTEMPELMAN, LINDA A | GINER, INC., MA | $224,587 | ZRG1 |
| 2015 | Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms1R41MH108219-01 | FELTON, JULIA W | MOUNTAINPASS TECHNOLOGY, LLC, MD | $224,573 | ZRG1 |
| 2015 | High Frequency Acceleration to Restore Alveolar Bone1R43DE025518-01 | WAY, BRYCE | PROPEL ORTHODONTICS, LLC, NY | $224,139 | ZRG1 |
| 2015 | BlueBox - a complete code blue data recorder1R41GM113463-01A1 | CHANG, RUEY-KANG | NEOVATIVE, INC., CA | $223,921 | ZRG1 |
| 2015 | Blood-based diagnostics for Alzheimer's Disease1R42AG049562-01 | SOTO, CLAUDIOVOLLRATH, BEN | AMPRION, INC., CA | $223,574 | ZRG1 |
| 2015 | Continuous measurement of cell growth as an optimal tool in drug toxicity testing1R41TR001196-01 | COOK, DANIEL L | ENTOX SCIENCES, LLC, WA | $223,503 | ZRG1 |
| 2015 | Identification of patients with diabetes at high risk for treatment failure1R41DK105612-01 | TURCHIN, ALEXANDER | LP INFORMATION TECHNOLOGY, MA | $223,336 | ZRG1 |
| 2015 | Validation and Cryopreservation of Ligament Engineered from Human Bone Marrow1R41AR066412-01A1 | ARRUDA, ELLEN MLARKIN, LISA M | STEL TECHNOLOGIES, LLC, MI | $222,922 | ZRG1 |
| 2015 | Semi-Automated Processing of Interconnected Dyads Using Entity Resolution (SPIDER)1R43MH106361-01A1 | HOPKINS, CHRISTOPHER M.YOUNG, APRIL MARIE | CHARLES RIVER ANALYTICS, INC., MA | $222,566 | ZRG1 |
| 2015 | Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatment1R41CA195923-01 | RYAZANOV, ALEXEY G. | LONGEVICA PHARMACEUTICALS, INC., NJ | $221,987 | ZRG1 |
| 2015 | Lowering the Cost of Imaging for Retinal Microvasculature in Diabetic Patients1R41EY026105-01 | ELSNER, ANN E | AEON IMAGING, LLC, IN | $221,519 | ZRG1 |
| 2015 | Engineering a phosphotyrosyl-tRNA Synthetase1R41GM113301-01 | WEINER, MICHAEL P | AXIOMX, INC., CT | $220,323 | ZRG1 |
| 2015 | Ultra-Sensitive Diagnosis of AIDS-Related Tuberculosis1R41AI118851-01 | CANGELOSI, GERARD A | ATTODX, INC., WA | $220,230 | ZRG1 |
| 2015 | MRI brain morphometry for computer-aided detection of neurological disorders1R44NS089090-01A1 | FISCHL, BRUCESCHMANSKY, NICHOLAS JOHN | CORTICOMETRICS, LLC, MA | $218,641 | ZRG1 |
| 2015 | Synthetic lubricin biomaterial for osteoarthritis1R41AR068183-01 | PUTNAM, DAVID A | ARTICULATE BIOMEDICAL, LLC, NY | $217,947 | ZRG1 |
| 2015 | Discovery of Oligodendrocyte Stimulators1R41NS095475-01 | RIVKEES, SCOTT A. | MEDOSOME BIOTEC, LLC, FL | $217,801 | ZRG1 |
| 2015 | Clonotyping Technology for Prediction of Antibiotic Resistance1R41AI116114-01 | APRIKIAN, PAVELSOKURENKO, EVGENI VENIAMINOVIC | IDGENOMICS, INC., WA | $214,436 | ZRG1 |
| 2015 | Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography1R41CA192645-01 | CHENG, JI-XIN | VIBRONIX, INC., IN | $212,978 | ZRG1 |
| 2015 | A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia1R41CA186505-01A1 | HOBAUGH, MARKPARKER, LAURIE L. | MICROFLUIDIC INNOVATIONS, LLC, IN | $211,754 | ZRG1 |
| 2015 | StrikeVEMP: Automated Portable Bone-Conducted Force Stimuli for Recording Acceleration-Produced coVEMPs1R41DC014874-01 | WACKYM, P. ASHLEY | EAR AND SKULL BASE CENTER, PC, OR | $211,604 | ZRG1 |
| 2015 | Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors1R41CA192656-01 | DURDEN, DONALD | SIGNALRX PHARMACEUTICALS, INC., GA | $209,001 | ZRG1 |
| 2015 | Asthmagram: objective assessment of asthma symptoms in children1R41HL127868-01 | CHANG, RUEY-KANG | NEOVATIVE, INC., CA | $207,102 | ZRG1 |
| 2015 | Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model1R41DE024946-01 | GOLUB, LORNE MGU, YING | TRAVERSE BIOSCIENCES, INC., NY | $205,709 | ZRG1 |
| 2015 | Family Supportive Supervisor Training and Workplace Assessment Tool1R41AG050347-01 | KOSSEK, ELLEN ERNST | WORK LIFE HELP, INC., MI | $201,333 | ZRG1 |
| 2015 | Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.1R41GM113529-01 | ZHU, YONG | VIVOSCRIPT, INC., CA | $200,082 | ZRG1 |
| 2015 | Peptide Based Therapy for Lung Fibrosis1R42HL127802-01 | FEGHALI-BOSTWICK, CAROL A.PADGETT, HAL S | NOVICI BIOTECH, LLC, CA | $199,999 | ZRG1 |
| 2015 | IRE1 alpha inhibitors for type 2 diabetes1R41DK108377-01 | BACKES, BRADLEY J | OPTIKIRA, LLC, OH | $199,611 | ZRG1 |
| 2015 | Shape Memory Polymer Foam Vascular Occlusion Device for the Treatment of Chronic Venous Insufficiency1R43EB022016-01A1 | LANDSMAN, TODD | SHAPE MEMORY MEDICAL INC., CA | $199,591 | ZRG1 |
| 2015 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model1R42AR066439-01A1 | GUILAK, FARSHID | CYTEX THERAPEUTICS INC., NC | $190,720 | ZRG1 |
| 2015 | TruEnamel: A dental product that treats, protects, desensitizes and whitens teeth1R41DE024011-01A1 | CLARKSON, BRIAN H | TRUENAMEL, LLC, MI | $188,406 | ZRG1 |
Showing the 200 most recent of 387 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.